Biosimilar development challenges

Biosimilars are surmounting pharmaceutical business division from most recent three decades and deals appear to extend coherently. Advances in the biotechnology prompt to change and exposure of new natural items (biosimilars) to treat diverse life-debilitating illnesses. Biosimilars are organic medications that are conveyed after expiry of the patent of affirmed pioneer and include Hatch-Waxman act is the amendment to Federal, Food, Drug and Cosmetics act which established the modern system of approval of generics through Abbreviated New Drug Applications (ANDAs).

  • Overview of the current and emerging local trends
  • Key changes in the pipeline of biopharma products
  • Highlighting opportunities and challenges in Biomanufacturing

Related Conference of Biosimilar development challenges

June 08-09, 2018

7th International conference on Pharmaceutical Auditing

Baltimore, Maryland, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
August 15-17, 2018

8th World Congress Spectroscopy and Analytical Techniques

Stockholm, Sweden
September 18-19, 2018

6th European Biopharma Congress

Amsterdam, Netherlands

Biosimilar development challenges Conference Speakers

Recommended Sessions

Related Journals

Are you interested in